Genetic Testing Can Help Prevent Serious Reactions To Seizure Medicines

What was studied

This paper describes a prescribing guideline, not a new clinical trial. It focuses on three medicines: carbamazepine, oxcarbazepine, and eslicarbazepine. These drugs are used for epilepsy, and carbamazepine is also used for bipolar disorder and trigeminal neuralgia.

The guideline addresses whether patients should have HLA genetic testing before starting these medicines, or if they have been taking them for less than 3 months. It highlights three HLA gene types linked to a higher risk of immune-mediated hypersensitivity reactions: HLA-B*15:02, HLA-B*15:11, and HLA-A*31:01. The recommendation applies to treatment-naive patients regardless of ancestry or reason for treatment.

What they found

The guideline says treatment-naive patients who are about to start carbamazepine, oxcarbazepine, or eslicarbazepine, or who have taken them for less than 3 months, should have pharmacogenetic testing for clinically relevant HLA alleles. The aim is to reduce the risk of hypersensitivity reactions, which typically affect the skin but can also involve the liver and other organ systems.

It recommends avoiding all three drugs in people who test positive for HLA-B*15:02. It also recommends avoiding them in people who test positive for HLA-A*31:01 or HLA-B*15:11 if another treatment can be used. If no alternative is available, the guideline says treatment should only start after careful weighing of risks and benefits, with increased monitoring and advice about what to do if a rash appears.

Limits of the evidence

This is a guideline based on existing evidence, not a study that directly tested outcomes in one group of patients. The abstract does not give numbers on how much testing lowers risk, how often these reactions happen, or how well testing works in different age groups.

The abstract also does not provide details about children specifically, long-term outcomes, cost, or how often people with these HLA types can still take the drugs safely. The authors note that the guideline cannot cover every individual situation, so clinical judgment is still needed.

For families and caregivers

For families, this suggests that a genetic test may help doctors choose safer treatment before starting certain seizure medicines. It may be important to ask about testing if carbamazepine, oxcarbazepine, or eslicarbazepine is being considered.

This does not mean everyone with a risk gene will definitely have a bad reaction, or that these medicines are unsafe for everyone. It means some people may have a higher risk, and testing may help guide the choice of medicine and monitoring plan.

What to watch next

Stronger evidence would include studies showing how routine HLA testing affects hypersensitivity reactions in real-world patients, including children.

Terms in this summary

HLA

A group of genes involved in how the immune system recognizes what belongs in the body and what does not.

genotype testing

A lab test that looks for specific gene variants.

pharmacogenetic testing

Genetic testing used to help predict how a person may react to a medicine.

hypersensitivity reaction

A harmful immune reaction to a medicine, which can range from a rash to a severe illness.

HLA-B*15:02

A specific HLA gene type linked to a higher risk of certain reactions to these medicines.

HLA-B*15:11

Another HLA gene type linked to a higher risk of drug hypersensitivity reactions.

HLA-A*31:01

An HLA gene type associated with a higher risk of immune-related reactions to these medicines.